STOCK TITAN

Verve Therapeutics, Inc. - VERV STOCK NEWS

Welcome to our dedicated page for Verve Therapeutics news (Ticker: VERV), a resource for investors and traders seeking the latest updates and insights on Verve Therapeutics stock.

Verve Therapeutics, Inc. (VERV) is a clinical-stage biotechnology pioneer developing single-course gene editing treatments for cardiovascular disease. This news hub provides investors and healthcare professionals with essential updates on therapeutic advancements, clinical trial progress, and strategic developments.

Access comprehensive coverage of VERV's innovative pipeline including PCSK9, ANGPTL3, and LPA gene editing programs. Our curated news collection features regulatory milestones, partnership announcements, and scientific breakthroughs in base editing technology.

Stay informed about Verve's cutting-edge approach to permanently modifying cholesterol-related genes through precise liver-targeted therapies. The page aggregates official press releases, trial result analyses, and expert commentary while maintaining strict financial compliance standards.

Bookmark this page for real-time updates on Verve Therapeutics' mission to transform cardiovascular care through durable genetic medicines. Check regularly for new developments in this rapidly evolving sector of precision biotechnology.

Rhea-AI Summary
Verve Therapeutics CEO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.89%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics appoints Fred Fiedorek as CMO, Andrew Bellinger transitions to CSO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.24%
Tags
management
-
Rhea-AI Summary
Verve Therapeutics, Inc. reported recent company progress and financial results for the second quarter of 2023. Their primary focus is on developing medicines targeting three pillars of cardiovascular risk: low-density lipoproteins (LDL), triglyceride-rich lipoproteins (TRL) and lipoprotein(a) (Lp(a)). They are expecting to report initial clinical data from the heart-1 Phase 1b clinical trial of VERVE-101 in the fourth quarter of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
-
Rhea-AI Summary
Verve Therapeutics announces exclusive research collaboration with Eli Lilly and Company to advance its gene editing program targeting lipoprotein(a) (Lp(a)). Verve will receive $60 million upfront payment and equity investment. Verve has opt-in rights to co-fund and share in potential margins of products resulting from the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.74%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.5%
Tags
conferences
Rhea-AI Summary

Verve Therapeutics announces participation in the Guggenheim 2023 Genomic Medicines and Rare Disease Day on April 3, 2023. CEO Sekar Kathiresan will engage in a fireside chat at 10:45 a.m. ET, providing insights into the company's innovative approaches to cardiovascular disease treatment through gene editing.

The event will be available via a live webcast on the company’s website, archived for 30 days. Verve focuses on VERVE-101 and VERVE-201, targeting genes to lower LDL cholesterol, addressing conditions like familial hypercholesterolemia and atherosclerotic cardiovascular disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
conferences
Verve Therapeutics, Inc.

Nasdaq:VERV

VERV Rankings

VERV Stock Data

407.57M
84.22M
5.04%
90.12%
16.74%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON